MX2021011983A - Compuestos de neuregulina-4 y metodos de uso. - Google Patents

Compuestos de neuregulina-4 y metodos de uso.

Info

Publication number
MX2021011983A
MX2021011983A MX2021011983A MX2021011983A MX2021011983A MX 2021011983 A MX2021011983 A MX 2021011983A MX 2021011983 A MX2021011983 A MX 2021011983A MX 2021011983 A MX2021011983 A MX 2021011983A MX 2021011983 A MX2021011983 A MX 2021011983A
Authority
MX
Mexico
Prior art keywords
compounds
neuregulin
methods
nrg4
nrg
Prior art date
Application number
MX2021011983A
Other languages
English (en)
Inventor
Josef George Heuer
Jonathan Wesley Day
James David Pancook
Wei Ni
Avinash Muppidi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021011983A publication Critical patent/MX2021011983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos de neuregulina (NRG) 4 y métodos de tratamiento con compuestos de NRG4.
MX2021011983A 2019-04-01 2020-03-31 Compuestos de neuregulina-4 y metodos de uso. MX2021011983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827386P 2019-04-01 2019-04-01
PCT/US2020/025921 WO2020205840A1 (en) 2019-04-01 2020-03-31 Neuregulin-4 compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2021011983A true MX2021011983A (es) 2021-11-03

Family

ID=70465394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011983A MX2021011983A (es) 2019-04-01 2020-03-31 Compuestos de neuregulina-4 y metodos de uso.

Country Status (23)

Country Link
US (2) US11242370B2 (es)
EP (1) EP3947428A1 (es)
JP (1) JP7036953B2 (es)
KR (1) KR20210134699A (es)
CN (1) CN113677699A (es)
AR (1) AR121035A1 (es)
AU (1) AU2020252184B2 (es)
BR (1) BR112021017670A2 (es)
CA (2) CA3132135A1 (es)
CL (1) CL2021002455A1 (es)
CO (1) CO2021012807A2 (es)
CR (1) CR20210474A (es)
DO (1) DOP2021000194A (es)
EA (1) EA202192288A1 (es)
EC (1) ECSP21072840A (es)
IL (1) IL286697A (es)
JO (1) JOP20210264A1 (es)
MA (1) MA55532A (es)
MX (1) MX2021011983A (es)
PE (1) PE20212326A1 (es)
SG (1) SG11202110484VA (es)
TW (1) TWI787596B (es)
WO (1) WO2020205840A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058828A1 (en) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023150693A2 (en) * 2022-02-03 2023-08-10 Avexegen Therapeutics, Inc. Neuregulin-4 analogs and methods of using thereof in disease treatment
WO2023230491A1 (en) 2022-05-25 2023-11-30 Eli Lilly And Company Methods of using neuregulin-4 compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
WO1999018976A1 (en) 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
WO2001014415A2 (en) 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
EP2357004B1 (en) 2000-05-23 2016-10-12 CeNeS Pharmaceuticals, Inc. NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods
EP1421113A4 (en) 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1660628A4 (en) 2003-08-19 2010-03-31 Agos Biotech Ltd ERBB LIGAND SPLICE VARIANTS, COMPOSITIONS AND USES THEREOF
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
AU2007257683A1 (en) * 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
ES2315110B1 (es) 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
CN101310779A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN101397337A (zh) * 2007-09-25 2009-04-01 上海泽生科技开发有限公司 神经调节蛋白突变体及其用途
ES2664394T3 (es) 2008-07-17 2018-04-19 Acorda Therapeutics, Inc. Dosificación terapéutica de una neuregulina o de una subsecuencia de la misma para el tratamiento o la profilaxis de la insuficiencia cardiaca
CA2734766A1 (en) 2008-08-15 2010-02-18 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
WO2010060266A1 (en) 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin and cardiac stem cells
US8609620B2 (en) 2008-11-28 2013-12-17 Zensun (Shanghai) Science & Technology Ltd. Neuregulin peptides and their use
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
US8889625B2 (en) 2009-07-10 2014-11-18 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
US20120121557A1 (en) 2009-07-22 2012-05-17 Children's Medical Center Corporation Neuregulin induced proliferation of cardiomyocytes
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
ES2745644T3 (es) 2011-08-15 2020-03-03 Los Angeles Childrens Hospital Uso de neuregulina-4 para el tratamiento de la enfermedad inflamatoria intestinal y la enterocolitis necrotizante
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US8748131B2 (en) 2012-09-26 2014-06-10 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
WO2014051567A1 (en) 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
WO2014056121A1 (en) 2012-10-08 2014-04-17 Zensun (Shanghai) Science & Technology Limited Compositions and methods for treating heart failure in diabetic patients
US20160129084A1 (en) 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
ES2751391T3 (es) 2013-03-21 2020-03-31 Univ Michigan Regents Procedimientos de tratamiento de trastornos metabólicos
AU2014270882B2 (en) 2013-05-22 2019-03-14 Zensun (Shanghai) Science & Technology, Co. Ltd. Extended release of neuregulin for treating heart failure
CN104211799B (zh) 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
US9352923B2 (en) 2014-02-26 2016-05-31 Eastman Kodak Company Air shoe with roller providing lateral constraint
WO2015158743A1 (en) 2014-04-15 2015-10-22 Universiteit Antwerpen Treatment of nephropathy
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US20170333529A1 (en) 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US10017574B2 (en) 2015-05-07 2018-07-10 Yeda Research And Development Co. Ltd. Methods, kits and devices for promoting cardiac regeneration
WO2017058828A1 (en) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
CN113166218A (zh) 2018-04-11 2021-07-23 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso

Also Published As

Publication number Publication date
CN113677699A (zh) 2021-11-19
TWI787596B (zh) 2022-12-21
PE20212326A1 (es) 2021-12-14
ECSP21072840A (es) 2021-11-18
TW202104251A (zh) 2021-02-01
SG11202110484VA (en) 2021-10-28
AU2020252184B2 (en) 2022-12-08
AR121035A1 (es) 2022-04-13
MA55532A (fr) 2022-02-09
EP3947428A1 (en) 2022-02-09
CO2021012807A2 (es) 2021-10-29
BR112021017670A2 (pt) 2021-11-16
IL286697A (en) 2021-10-31
CR20210474A (es) 2021-10-13
US20200354421A1 (en) 2020-11-12
JP7036953B2 (ja) 2022-03-15
EA202192288A1 (ru) 2022-01-21
JP2021522314A (ja) 2021-08-30
CL2021002455A1 (es) 2022-05-27
US11242370B2 (en) 2022-02-08
DOP2021000194A (es) 2021-10-31
US20220112255A1 (en) 2022-04-14
CA3132135A1 (en) 2020-10-08
KR20210134699A (ko) 2021-11-10
WO2020205840A1 (en) 2020-10-08
JOP20210264A1 (ar) 2023-01-30
CA3223554A1 (en) 2020-10-08
AU2020252184A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JOP20210264A1 (ar) مركبات نورجولين-4 وطرق استخدامها
MX2020013853A (es) Compuestos innovadores.
MX2022012474A (es) Compuestos y usos de estos.
MX2020006191A (es) Bacteriocinas terapeuticas.
ZA202207804B (en) Compounds and uses thereof
MX2022001004A (es) Inhibidores de enzimas.
MX2022009369A (es) Compuestos y usos de estos.
MX2021012659A (es) Composiciones de seda para el cuidado del cabello.
MX2022009308A (es) Compuestos y usos de estos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2022003037A (es) Compuestos antibacterianos.
PH12021550122A1 (en) Solubilized apyrases, methods and use
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2022009367A (es) Compuestos y usos de estos.
MX2022000811A (es) Inhibidores de enzimas.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
MX2021006977A (es) Anellosomas y metodos de uso.
MX2023005436A (es) Compuestos y usos de estos.
AU2020378127A8 (en) Compounds as CD73 inhibitors
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2022003030A (es) Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab.
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
MX2021014220A (es) Composiciones para el tratamiento de la perdida del cabello.
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.